Aimmune Therapeutics Inc. (AIMT) Stock Price Down 3%
Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price traded down 3% during mid-day trading on Thursday . The stock traded as low as $10.14 and last traded at $10.32, with a volume of 164,021 shares traded. The stock had previously closed at $10.64.
Several equities analysts have recently issued reports on the stock. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Tuesday, June 14th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, June 13th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, May 20th. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $33.40.
The stock’s market capitalization is $443.17 million. The company has a 50-day moving average of $13.06 and a 200 day moving average of $14.66.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, May 16th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. On average, equities analysts predict that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a filing with the SEC, which is available at this link.
A number of hedge funds and institutional investors recently modified their holdings of the company. TLP Group LLC bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at about $51,314,000. Aisling Capital LLC increased its position in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares during the period. Finally, Alps Advisors Inc. bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at about $1,027,000.
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.